PE20060362A1 - Compuestos de oxazol como moduladores de ppar - Google Patents

Compuestos de oxazol como moduladores de ppar

Info

Publication number
PE20060362A1
PE20060362A1 PE2005000563A PE2005000563A PE20060362A1 PE 20060362 A1 PE20060362 A1 PE 20060362A1 PE 2005000563 A PE2005000563 A PE 2005000563A PE 2005000563 A PE2005000563 A PE 2005000563A PE 20060362 A1 PE20060362 A1 PE 20060362A1
Authority
PE
Peru
Prior art keywords
metoxy
phenoxy
alkylene
methyl
acetic
Prior art date
Application number
PE2005000563A
Other languages
English (en)
Inventor
Yongping Xie
Christopher Cow
Ross Russo
Xing Wang
Robert Epple
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of PE20060362A1 publication Critical patent/PE20060362A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS DE OXAZOL DE FORMULA (I), EN DONDE p ES DE 0 A 3; L2 ES -XOX-, -XS(O)0-2X-, Y -XS(O)0-2XO-, EN DONDE X ES UN ENLACE A PARTIR DE ALQUILENO(C1-C4) OPCIONALMENTE SUSTITUIDO; R13 ES ALQUILO O ALCOXILO(C1-C6), HALOGENO, ENTRE OTROS; R14 ES -XOXC(O)OR17 Y -XC(O)OR17, EN DONDE X ES UN ENLACE O ALQUILENO(C1-C4) Y R17 ES H O ALQUILO(C1-C6); R15 Y R17 SON INDEPENDIENTEMENTE -R18 O -YR18, EN DONDE Y ES ALQUILENO(C1-C6), ALQUENILENO(C2-C6), -C(O)NR17- Y -OX; R18 ES ARILO(C6-C10), CICLOALQUILO(C3-C12) Y HETEROARILO(C5-C13), ENTRE OTROS Y OPCIONALMENTE SUSTITUIDOS. SON PREFERIDOS: ACIDO {4-[4,5-BIS(4-METOXI-FENIL)-OXAZOL-2-IL-METOXI]-2-METIL-FENOXI}-ACETICO, ACIDO {4-[5-BIFENIL-4-IL-4-(4-METOXIFENIL)-OXAZOL-2-IL-METOXI]-2-METIL-FENOXI}-ACETICO, ACIDO {4-[4-(6-ISOPROPOXI-PIRIDIN-3-IL)-5-(4-TRIFLUORO-METOXI-FENIL)-OXAZOL-2-ILMETOXI]-2-METIL-FENOXI}-ACETICO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ADEMAS PUEDE CONTENER OTRO AGENTE ACTIVO TAL COMO ANTIDIABETICOS, HIPOLIPIDEMICOS, ENTRE OTROS. ESTOS COMPUESTOS SON MODULADORES DEL REECEPTOR ACTIVADO POR PROLIFERADOR DE PEROXISOMAS PARTICULARMENTE DE PPAR*, POR LO QUE SON UTILES EN EL TRATAMIENTO DE DISLIPIDEMIAS, HIPERCOLESTEREMIA, HIPERLIPIDEMIA, INSUFICIENCIA CARDIACA, HIPERTENSION, OBESIDAD Y ENFERMEDADES RELACIONADAS
PE2005000563A 2004-05-24 2005-05-20 Compuestos de oxazol como moduladores de ppar PE20060362A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57413704P 2004-05-24 2004-05-24
US64967105P 2005-02-02 2005-02-02

Publications (1)

Publication Number Publication Date
PE20060362A1 true PE20060362A1 (es) 2006-05-15

Family

ID=35450825

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000563A PE20060362A1 (es) 2004-05-24 2005-05-20 Compuestos de oxazol como moduladores de ppar

Country Status (17)

Country Link
US (1) US20070244130A1 (es)
EP (1) EP1749003A4 (es)
JP (1) JP2008500354A (es)
KR (1) KR20070043705A (es)
AR (1) AR049186A1 (es)
AU (2) AU2005247930B2 (es)
BR (1) BRPI0511527A (es)
CA (1) CA2563819A1 (es)
EC (1) ECSP067019A (es)
IL (1) IL179375A0 (es)
MA (1) MA28900B1 (es)
MX (1) MXPA06013589A (es)
NO (1) NO20065983L (es)
PE (1) PE20060362A1 (es)
RU (1) RU2412175C2 (es)
TW (1) TW200600505A (es)
WO (1) WO2005116016A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2625646A1 (en) * 2005-10-25 2007-05-03 Merck & Co., Inc. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
JP2009514974A (ja) * 2005-11-07 2009-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｐａｒモジュレーターとしての化合物および組成物
JP5175866B2 (ja) * 2007-02-22 2013-04-03 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇタンパク質共役受容体を調節するための化合物および方法
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
KR100860561B1 (ko) * 2007-05-02 2008-09-26 경희대학교 산학협력단 컴파운드 ｋ 및 메트포민을 유효성분으로 포함하는당뇨병의 예방 및 치료용 약학적 조성물
US20100113604A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
WO2010045416A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
US20100113581A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100113603A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100331419A1 (en) * 2009-06-25 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
WO2010151565A2 (en) * 2009-06-26 2010-12-29 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
US20100331999A1 (en) * 2009-06-29 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20110015663A1 (en) * 2009-07-17 2011-01-20 Aronne Louis J Combination Therapies for the Treatment of Obesity
CA2770405C (en) * 2009-08-05 2015-03-17 Daiichi Sankyo Company, Limited Sulfone derivative
MX2012001107A (es) * 2009-08-05 2012-03-26 Daiichi Sankyo Co Ltd Derivado de amida.
US20110082407A1 (en) * 2009-10-01 2011-04-07 Aronne Louis J Combination Therapies for the Treatment of Obesity
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103724289B (zh) * 2013-12-23 2015-08-19 同济大学 (e)-2,4,5-三取代-(1-丙烯基)噁唑环类化合物及合成方法和应用
CN104402839B (zh) * 2014-10-20 2016-11-02 同济大学 一种(e)-2,4,5-三取代-(1-丙烯基)噁唑环类化合物及其制备方法
CN108760940A (zh) * 2018-08-03 2018-11-06 安徽省金楠医疗科技有限公司 一种硫酸氢氯吡格雷检测方法
CN112521384B (zh) * 2021-01-13 2021-11-02 湖北大学 溶剂热一锅法合成苯并噻嗪并环戊二烯衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4325959A (en) * 1979-08-09 1982-04-20 The Dow Chemical Company Hypoglycemic 4-(((1,3,4, thiadiazolyl)thio)methyl)benzoic acids, ester and amides
JPH0662590B2 (ja) * 1986-09-19 1994-08-17 久光製薬株式会社 新規なベンズオキサゾ−ル誘導体
IT1229491B (it) * 1988-12-28 1991-09-03 Roussel Maestretti S P A Ora R Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
US5262540A (en) * 1989-12-20 1993-11-16 Bristol-Myers Squibb Company [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
NZ236474A (en) * 1989-12-20 1993-07-27 Bristol Myers Squibb Co 4,5-diphenyl-2-oxazole octanoic, nonanoic and decanoic acid and ester derivatives, preparation and pharmaceutical compositions thereof
IT1248528B (it) * 1991-06-21 1995-01-19 Pierrel Spa Derivati di eteri e tioeteri (etero) aromatici aventi attivita` antiiperlipidemica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
JPH06206805A (ja) * 1992-02-17 1994-07-26 Hisamitsu Pharmaceut Co Inc チロシナーゼ阻害剤及びそれを用いた皮膚外用剤
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
JPH11147881A (ja) * 1997-08-21 1999-06-02 Sankyo Co Ltd ジヒドロベンゾキノン骨格を有する除草性アゾール誘導体
JP2002348281A (ja) * 2001-03-23 2002-12-04 Takeda Chem Ind Ltd ５員複素環アルカン酸誘導体

Also Published As

Publication number Publication date
ECSP067019A (es) 2006-12-29
EP1749003A4 (en) 2010-05-05
KR20070043705A (ko) 2007-04-25
AR049186A1 (es) 2006-07-05
JP2008500354A (ja) 2008-01-10
IL179375A0 (en) 2007-03-08
AU2009202673A1 (en) 2009-07-23
TW200600505A (en) 2006-01-01
CA2563819A1 (en) 2005-12-08
MXPA06013589A (es) 2007-03-15
EP1749003A1 (en) 2007-02-07
AU2005247930A1 (en) 2005-12-08
RU2006145893A (ru) 2008-06-27
AU2005247930B2 (en) 2009-04-02
BRPI0511527A (pt) 2008-01-02
WO2005116016A1 (en) 2005-12-08
US20070244130A1 (en) 2007-10-18
RU2412175C2 (ru) 2011-02-20
MA28900B1 (fr) 2007-10-01
NO20065983L (no) 2007-02-05

Similar Documents

Publication Publication Date Title
PE20060362A1 (es) Compuestos de oxazol como moduladores de ppar
PE20060315A1 (es) Compuestos de tiazol como moduladores de ppar
RU2379299C2 (ru) Производные 5-(бенз-(z)-илиден)тиазолидин-4-она и их применение в качестве иммуносупрессорных агентов
PE20080858A1 (es) Compuestos de n-aril pirazol y composiciones que los contienen
PE20060427A1 (es) Derivados de pirazol como inhibidores de la union del glucagon y composiciones
PE20090297A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis
RU2009118281A (ru) Гетероциклические ингибиторы мек и способы их применения
PE20110341A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
PE20060357A1 (es) Compuestos y composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
PE20060306A1 (es) Compuestos de heteroaril-amida sustituida
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20080251A1 (es) Usos de inhibidores de dpp iv
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20090694A1 (es) Compuestos moduladores de sirtuinas
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
RU2011106374A (ru) Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
PE20080927A1 (es) Derivados de benzoil-amino-heterociclilo como activadores de la glucoquinasa (glk)
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20060999A1 (es) Composiciones farmaceuticas que contienen un diuretico y un bloqueador del receptor de angiotensina ii
PE20110136A1 (es) Compuestos organicos
PE20020722A1 (es) Derivados de glucopiranosiloxipirazol como inhibidor del sglt2 humano
PE20090641A1 (es) Amidas heterociclicas
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2

Legal Events

Date Code Title Description
FC Refusal